-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

Benzinga·11/11/2026 15:18:44
Listen to the news
RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.